EPIPROATE CR-300 300MG TABLET

Indications

• Hyponatremia
• Hypovolemia
• Electrolyte replacement
• Fluid resuscitation

Dosage

Children: Pediatric dosing should be determined based on the child's condition, age, weight, and clinical guidelines. Refer to the BNF for Children for specific dosing information.

Adults: Sodium replacement therapy and dosage depend on the clinical condition and are usually administered in a controlled medical setting. It is crucial to refer to specific guidelines or protocols for dosing recommendations.

Mechanism of action

Sodium functions mainly by maintaining the electrochemical gradient across cell membranes, which is crucial for the propagation of action potentials in neurons and muscle cells. It is actively transported into cells via sodium-potassium ATPase pumps, and it influences the movement of water across cell membranes through osmosis.

Pharmacodynamics

Sodium ions are vital for various physiological processes, including the regulation of blood pressure, the conduction of electrical impulses in nerves and muscles, and the maintenance of acid-base balance. Changes in sodium levels can significantly affect cellular functions and overall homeostasis.

Pharmacokinetics

Sodium is absorbed primarily in the gastrointestinal tract, with the kidneys playing a key role in regulating sodium excretion. The balance of sodium is tightly controlled by hormones such as aldosterone, which promotes sodium reabsorption in the renal tubules. The plasma half-life of sodium is variable but is generally related to dietary intake and renal function.

Contra-indications

• Hypersensitivity to sodium or any component of the formulation
• Severe renal impairment
• Hypernatremia
• Heart failure
• Edema associated with renal failure

Adverse effects

• Fluid retention
• Hypertension
• Edema
• Hypernatremia
• Nausea
• Vomiting
• Muscle spasms
• Confusion
• Seizures (in severe cases)

Interactions

• Diuretics (particularly thiazide and loop diuretics)
• ACE inhibitors
• Angiotensin II receptor antagonists
• Lithium (sodium can affect lithium levels)
• Nonsteroidal anti-inflammatory drugs (NSAIDs)

Precautions

• Monitor serum sodium levels regularly
• Use with caution in patients with cardiovascular disease
• Caution in patients with liver disease
• Assess fluid balance in patients receiving sodium supplementation

Pregnancy

Sodium is generally considered safe during pregnancy, but excessive intake should be avoided to prevent fluid retention and hypertension.

Breast-feeding

Sodium is excreted in breast milk, but dietary intake is usually safe; excessive supplementation should be avoided.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Sodium chloride injection
• Sodium bicarbonate tablets
• Sodium acetate solution
• Sodium citrate oral solution

Indications

• Epilepsy
• Bipolar disorder
• Migraine prophylaxis

Dosage

Children: For children, the initial dosage typically starts at 10-15 mg/kg/day, divided into two or three doses. The dose may be increased by 5-10 mg/kg/week

Adults: The usual starting dose for adults is 600 mg daily in divided doses, which can be gradually increased based on clinical response and tolerability. The maximum recommended dose is generally around 2,500 mg per day, but this can vary based on individual patient factors.

Mechanism of action

Valproate primarily enhances the levels of GABA in the brain by inhibiting its degradation and increasing its synthesis. It also modulates voltage-gated sodium channels, stabilizing the neuronal membrane and preventing excessive neuronal firing. Additionally, valproate may influence various signaling pathways, including histone deacetylase inhibition, contributing to its neuroprotective effects.

Pharmacodynamics

Valproate exhibits dose-dependent pharmacological effects, leading to increased GABAergic activity and reduced excitatory neurotransmission. This results in its anticonvulsant, mood-stabilizing, and migraine-preventive properties. The therapeutic effect is often accompanied by a predictable side effect profile, including sedation, weight gain, and potential hepatotoxicity.

Pharmacokinetics

Valproate is well absorbed from the gastrointestinal tract, with peak plasma concentrations occurring within 1 to 4 hours after oral administration. It is extensively protein-bound, primarily to albumin. The drug undergoes hepatic metabolism, primarily through glucuronidation and beta-oxidation, producing several metabolites. The elimination half-life ranges from 9 to 16 hours. It is excreted in the urine as metabolites, and dosage adjustments may be necessary in cases of hepatic impairment.

Contra-indications

• Hypersensitivity to valproate or any of its components
• Severe liver impairment
• Urea cycle disorders
• Pregnancy in women with epilepsy unless no alternative treatment is appropriate

Adverse effects

• Nausea
• Vomiting
• Drowsiness
• Tremor
• Weight gain
• Hepatotoxicity
• Pancreatitis
• Thrombocytopenia
• Cognitive impairment
• Hair loss

Interactions

• valproate+penicillins: Severe (increases risk of adverse effects)
• valproate+pivmecillinam: Severe (increases risk of adverse effects)
• valproate+antipsychotics, second generation: Moderate (increases exposure)
• valproate+paliperidone: Moderate (increases exposure)
• valproate+calcium channel blockers: Moderate (increases exposure)
• valproate+nimodipine: Moderate (increases exposure)
• cannabidiol+valproate: Moderate (increases risk of increased alt concentrations)
• guanfacine+valproate: Moderate (increases concentration)
• valproate+propofol: Moderate (increases concentration)
• apalutamide+valproate: Unknown (decreases exposure)

Precautions

• Monitor liver function tests prior to and during treatment
• Use with caution in patients with hepatic impairment
• Assess for potential drug interactions
• Consider risk of teratogenic effects in women of childbearing age

Pregnancy

Valproate is contraindicated in pregnancy for the treatment of epilepsy unless no alternative treatment is appropriate, as it is associated with a high risk of teratogenic effects.

Breast-feeding

Valproate is excreted in breast milk. Caution is advised when administering to breastfeeding mothers, considering potential effects on the infant.

Storage

Store below 25°C. Protect from light. Keep out of reach of children.

Formulations

• Tablets
• Oral solution
• Capsules
• Sustained-release tablets